CMRX Key Stats
|Revenue (Quarterly YoY Growth)||Upgrade|
|EPS Diluted (TTM)||-3.156|
|EPS Diluted (Quarterly YoY Growth)||Upgrade|
|Net Income (TTM)||-37.72M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-1331%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM)||Upgrade|
Street Insider06/23 16:22
|06/20/2014||Misc||Annual General Meeting for Chimerix Inc|
CMRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Chimerix is down 9.45% over the last year vs S&P 500 Total Return up 19.93%, ARCA biopharma up 3.57%, and Xencor up N/A.
Income Statement View Statement
Balance Sheet View Statement
Y-Ratings for CMRX
Portfolio Strategies Featuring CMRX
Did Chimerix make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Company Website: http://www.chimerix.com
- IR Website: http://ir.chimerix.com/
- HQ Country: United States
- HQ State/Province: North Carolina
- Incorporation Country: United States
- Incorporation State/Province: Delaware
- Est. Current Fiscal Quarter End: June 30, 2014
- Est. Current Fiscal Year End: December 31, 2014
- Last Fiscal Quarter End: March 31, 2014
- Last Fiscal Year End: December 31, 2013
- NAICS: Pharmaceutical Preparation Manufacturing
- NAICS Code: 325412
- NAICS Industry: Pharmaceutical and Medicine Manufacturing
- NAICS Sector: Manufacturing
Chimerix Inc is a biopharmaceutical company that develops and commercializes oral antivirals. It has two compounds in clinical development: CMX001 and CMX157.
CMRX Excel Add-In Codes
- Name: =YCI("CMRX","name")
- Description: =YCI("CMRX","description")
- Sector: =YCI("CMRX","sector")
- Industry: =YCI("CMRX","industry")
- Est. Current Fiscal Year End: =YCI("CMRX","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.